Takeda Pharmaceutical Co Ltd
4502: XTKS (JPN)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
¥1,769.00 | Gxgp | Qjtqdbsd |
Takeda Earnings: Results and Guidance in Line, Moat Rating Downgrade to None
Takeda’s fourth-quarter earnings and fiscal 2024 guidance were in line with our expectations. Separately, we lower our moat rating to no-moat from narrow. Despite our downgraded rating, we maintain our fair value estimate of JPY 4,700, as our previous fair value reflected sufficiently conservative assumptions.